

# Emtricitabine

NOT RECOMMENDED AS AN  
ESSENTIAL MEDICINE

Section: 6. Anti-infective medicines > 6.4. Antiviral medicines > 6.4.2. Antiretrovirals > 6.4.2.1. Antiretrovirals >  
Nucleoside/Nucleotide reverse transcriptase inhibitors

EMLc

ATC codes: J05AF09

|                          |   |
|--------------------------|---|
| Indication               | Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified ICD11 code: <a href="#">1C62.Z</a>                        |
| INN                      | Emtricitabine   |
| Medicine type            | Chemical agent  |
| List type                | Core (EML) (EMLc)   |
| Additional notes         | Emtricitabine (FTC) is an acceptable alternative to lamivudine (3TC), based on knowledge of the pharmacology, the resistance patterns and clinical trials of antiretrovirals. |
| Formulations             | Oral > Liquid: 10 mg per mL<br>Oral > Solid: 200 mg   |
| EML status history       | First added in 2007 ( <a href="#">TRS 946</a> )<br>Changed in 2007 ( <a href="#">TRS 950</a> )<br>Removed in 2015 ( <a href="#">TRS 994</a> )                                 |
| Sex                      | All   |
| Age                      | Also recommended for children   |
| Age restriction          | >3 months   |
| Therapeutic alternatives | The recommendation is for this specific medicine  |
| Patent information       | Patents have expired in most jurisdictions<br>Read more <a href="#">about patents</a> . <a href="#">↗</a>   |
| Wikipedia                | <a href="#">Emtricitabine</a> <a href="#">↗</a>   |
| DrugBank                 | <a href="#">Emtricitabine</a> <a href="#">↗</a>   |

## Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the removal of emtricitabine from the EML and EMLc on the basis that listing is not aligned with dosing guidelines in the 2013 WHO Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection (1), and also because of the availability of fixed-dose combination formulations containing emtricitabine. References: 1. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013. Available from: [http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf).

